489 related articles for article (PubMed ID: 19932713)
21. Selective prostacyclin receptor agonism augments glucocorticoid-induced gene expression in human bronchial epithelial cells.
Wilson SM; Shen P; Rider CF; Traves SL; Proud D; Newton R; Giembycz MA
J Immunol; 2009 Nov; 183(10):6788-99. PubMed ID: 19880449
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroids: the drugs to beat.
Barnes PJ
Eur J Pharmacol; 2006 Mar; 533(1-3):2-14. PubMed ID: 16436275
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations.
Gibson PG; Powell H; Ducharme FM
J Allergy Clin Immunol; 2007 Feb; 119(2):344-50. PubMed ID: 17291852
[TBL] [Abstract][Full Text] [Related]
24. Impact of protein acetylation in inflammatory lung diseases.
Ito K; Charron CE; Adcock IM
Pharmacol Ther; 2007 Nov; 116(2):249-65. PubMed ID: 17720252
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids.
Chivers JE; Gong W; King EM; Seybold J; Mak JC; Donnelly LE; Holden NS; Newton R
Mol Pharmacol; 2006 Dec; 70(6):2084-95. PubMed ID: 16988013
[TBL] [Abstract][Full Text] [Related]
26. No association of glucocorticoid receptor polymorphisms with asthma and response to glucocorticoids.
Szczepankiewicz A; Breborowicz A; Sobkowiak P; Popiel A
Adv Med Sci; 2008; 53(2):245-50. PubMed ID: 18952539
[TBL] [Abstract][Full Text] [Related]
27. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
Blanchette CM; Culler SD; Ershoff D; Gutierrez B
Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
[TBL] [Abstract][Full Text] [Related]
28. [New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids].
Huisman AM; Jacobs JW; Buttgereit F; Bijlsma JW
Ned Tijdschr Geneeskd; 2006 Mar; 150(9):476-80. PubMed ID: 16553045
[TBL] [Abstract][Full Text] [Related]
29. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Giembycz MA; Newton R
Handb Exp Pharmacol; 2011; (204):415-46. PubMed ID: 21695651
[TBL] [Abstract][Full Text] [Related]
30. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.
Giembycz MA; Kaur M; Leigh R; Newton R
Br J Pharmacol; 2008 Mar; 153(6):1090-104. PubMed ID: 18071293
[TBL] [Abstract][Full Text] [Related]
31. Update on glucocorticoid action and resistance.
Ito K; Chung KF; Adcock IM
J Allergy Clin Immunol; 2006 Mar; 117(3):522-43. PubMed ID: 16522450
[TBL] [Abstract][Full Text] [Related]
32. Treating asthma: is there a place for leukotriene receptor antagonists?
Diamant Z; van der Molen T
Respir Med; 2005 Jun; 99(6):655-62. PubMed ID: 15878481
[TBL] [Abstract][Full Text] [Related]
33. [Friend or foe: combination therapy with inhaled corticosteroids and long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD)].
Gillissen A; Gessner C; Hoheisel G; Juergens U
Pneumologie; 2008 Jul; 62(7):430-7. PubMed ID: 18398787
[TBL] [Abstract][Full Text] [Related]
34. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications.
Tamimi A; Serdarevic D; Hanania NA
Respir Med; 2012 Mar; 106(3):319-28. PubMed ID: 22196881
[TBL] [Abstract][Full Text] [Related]
35. Mode of glucocorticoid actions in airway disease.
Ito K; Getting SJ; Charron CE
ScientificWorldJournal; 2006 Dec; 6():1750-69. PubMed ID: 17195873
[TBL] [Abstract][Full Text] [Related]
36. Optimized glucocorticoid therapy: teaching old drugs new tricks.
Strehl C; Buttgereit F
Mol Cell Endocrinol; 2013 Nov; 380(1-2):32-40. PubMed ID: 23403055
[TBL] [Abstract][Full Text] [Related]
37. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases.
Kato M; Hagiwara Y; Oda T; Imamura-Takai M; Aono H; Nakamura M
J Ocul Pharmacol Ther; 2011 Aug; 27(4):353-60. PubMed ID: 21574866
[TBL] [Abstract][Full Text] [Related]
38. Strategies for improving the efficacy and therapeutic ratio of glucocorticoids.
Adcock IM; Caramori G; Kirkham PA
Curr Opin Pharmacol; 2012 Jun; 12(3):246-51. PubMed ID: 22445282
[TBL] [Abstract][Full Text] [Related]
39. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
Schäcke H; Schottelius A; Döcke WD; Strehlke P; Jaroch S; Schmees N; Rehwinkel H; Hennekes H; Asadullah K
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):227-32. PubMed ID: 14694204
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
Adcock IM; Ito K
Proc Am Thorac Soc; 2005; 2(4):313-9; discussion 340-1. PubMed ID: 16267355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
